Physician profile
Sunil Raichand
NPI 1740354455
$2,619.70
in general payments reported to CMS, 2019-2025
14 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $192 · 2021: $888 · 2022: $38.53 · 2023: $498 · 2024: $551 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $752.00 | 2021 | |
| Biotissue Holdings INC. | $521.36 | 2023-2024 | |
| Allergan, INC. | $322.70 | 2019-2020 | |
| Alcon Vision LLC | $281.89 | 2019-2025 | Rocklatan |
| Harrow Eye, LLC | $163.08 | 2024 | Iheezo |
| Johnson & Johnson Surgical Vision, INC. | $127.84 | 2023-2025 | Catalys System, Tecnis Simplicity, Tecnis Iol |
| Carl Zeiss Meditec USA, INC. | $120.45 | 2021 | |
| Apellis Pharmaceuticals, INC. | $102.53 | 2023 | Syfovre |
| Oyster Point Pharma, INC. | $72.14 | 2023-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $45.43 | 2022-2024 | Xiidra, Miebo |
| Amgen INC. | $42.28 | 2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $29.30 | 2021-2022 | |
| Dompe US, INC. | $23.59 | 2024 | Oxervate |
| Boston Scientific Corporation | $15.11 | 2023 | Advantage System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Raichand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.